Winston Pharmaceuticals, Inc.
WPHM
Other OTC0.00
USD
- -
- -
ISIN
US9756571074
CUSIP
975657107
Return %
Stock
S&P500
1Y
-66.67
24.43
3Y
-99.89
71.69
5Y
-99.89
77.43
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Joel E. Bernstein
- Full Time Employees
- 9
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- Address
- 100 North Fairway Drive Vernon Hills United States of America
- IPO Date
- Jun 5, 2023
- Website
- winstonlabs.com
- Similar Companies
- Business
- Winston Pharmaceuticals, Inc. (WPHM) operates as a specialty pharmaceutical company focused on the discovery, development, and commercialization of therapeutics for pain management; its pipeline targets major indications including episodic cluster headache, chronic migraine headache, neuropathic pain syndromes, osteo- and rheumatoid arthritis, and pain and inflammation associated with inflammatory bowel disease, as well as niche pain conditions such as post-traumatic neuralgia, mucositis, pruritus, and acne vulgaris. The company offers late-stage candidates like zucapsaicin for post-traumatic neuralgia, cidoxepin for allergic rhinitis, carbamide peroxide for acne vulgaris, WL-1009 for mucositis, and E-0316 for pruritus, serving healthcare providers and patients in the United States through its OTC-traded common stock. Founded in 1992 by Joel E. Bernstein, who serves as CEO, and headquartered in Vernon Hills, Illinois, Winston Pharmaceuticals employs approximately nine staff and maintains operations primarily in the U.S. healthcare sector. In recent developments, the company, formerly known as Winston Laboratories, Inc., completed a merger with Getting Ready, Inc. in 2018, emerging as the surviving entity under its current name with Bernstein leading as CEO and chairman; it last reported trailing twelve-month revenue of $1.37 million and net losses of $2.34 million as of data through 2010, with no disclosed funding rounds, acquisitions, or new product launches in the past 1-2 years amid minimal public updates.